The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CHEMBL76399     N'-propyl-4,5,6,7- tetrahydrobenzothiazole...

Synonyms: BEN629, CHEBI:217022, AR-1D4657, HMS3393A21, AC1L1J65, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of pramipexole


Psychiatry related information on pramipexole


High impact information on pramipexole

  • After 3-4 h of infusion, when the expected natriuresis (fenoldopam or pramipexole) or antinatriuresis (NE) occurred, the kidneys were removed for analysis of PLC isoform protein expression activity [10].
  • Other criticisms include insufficient data on the use of the potential neuroprotectant selegiline and patients on pramipexole in the SPECT study appear to have been clinically slow progressors [11].
  • At clinically relevant doses, pramipexole produced statistically robust decreases in rCBF in bilateral orbitofrontal cortex, thalamus, operculum, posterior and anterior (subgenual) cingulate cortex, and insula (in decreasing order of significance) [12].
  • A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications [1].
  • We also found that the agonist pramipexole failed to stimulate activation of Akt in PC12-D2R cells, providing an explanation for our previous observations that, despite efficiently activating G-protein signaling, this agonist had little cytoprotective activity in this experimental system [13].

Chemical compound and disease context of pramipexole


Biological context of pramipexole


Anatomical context of pramipexole


Associations of pramipexole with other chemical compounds


Gene context of pramipexole


Analytical, diagnostic and therapeutic context of pramipexole

  • CONCLUSION: In a subset of patients with fibromyalgia, approximately 50% of whom required narcotic analgesia and/or were disabled, treatment with pramipexole improved scores on assessments of pain, fatigue, function, and global status, and was safe and well-tolerated [1].
  • Thirty clinically asymmetrical patients were randomly assigned to receive 6 weeks of L-dopa (300/75 mg/d), pramipexole (1.5 mg/d), or placebo; PET studies were performed before and after treatment [31].
  • A double-blind, randomized, multicenter study was performed to compare the safety, tolerance, and efficacy of pramipexole versus placebo in patients with advanced PD with motor fluctuations [32].
  • Because of concern regarding driving safety, we evaluated the incidence and nature of somnolence experienced by patients receiving pramipexole in clinical trials at our center [33].
  • Plasma and urine samples collected within the four dose intervals were assayed for concentrations of pramipexole, using high-performance liquid chromatography [34].


  1. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Holman, A.J., Myers, R.R. Arthritis Rheum. (2005) [Pubmed]
  2. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Kitamura, Y., Kosaka, T., Kakimura, J.I., Matsuoka, Y., Kohno, Y., Nomura, Y., Taniguchi, T. Mol. Pharmacol. (1998) [Pubmed]
  3. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Shannon, K.M., Bennett, J.P., Friedman, J.H. Neurology (1997) [Pubmed]
  4. Pramipexole in progressive supranuclear palsy. Weiner, W.J., Minagar, A., Shulman, L.M. Neurology (1999) [Pubmed]
  5. Pramipexole in refractory bipolar depression. Goldberg, J.F., Frye, M.A., Dunn, R.T. The American journal of psychiatry. (1999) [Pubmed]
  6. Pramipexole augmentation in panic with agoraphobia. Marazziti, D., Presta, S., Pfanner, C., Dell'Osso, L., Cassano, G.B. The American journal of psychiatry. (2001) [Pubmed]
  7. Encouraging initial response of restless legs syndrome to pramipexole. Becker, P.M., Ondo, W., Sharon, D. Neurology (1998) [Pubmed]
  8. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. Siuciak, J.A., Fujiwara, R.A. Psychopharmacology (Berl.) (2004) [Pubmed]
  9. Pharmacological management of Huntington's disease: an evidence-based review. Bonelli, R.M., Wenning, G.K. Curr. Pharm. Des. (2006) [Pubmed]
  10. Differential regulation of renal phospholipase C isoforms by catecholamines. Yu, P.Y., Asico, L.D., Eisner, G.M., Jose, P.A. J. Clin. Invest. (1995) [Pubmed]
  11. Dopamine agonist monotherapy in Parkinson's disease. Clarke, C.E., Guttman, M. Lancet (2002) [Pubmed]
  12. A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist. Black, K.J., Hershey, T., Koller, J.M., Videen, T.O., Mintun, M.A., Price, J.L., Perlmutter, J.S. Proc. Natl. Acad. Sci. U.S.A. (2002) [Pubmed]
  13. Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor. Nair, V.D., Sealfon, S.C. J. Biol. Chem. (2003) [Pubmed]
  14. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Etminan, M., Gill, S., Samii, A. Drug safety : an international journal of medical toxicology and drug experience. (2003) [Pubmed]
  15. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Willner, P., Lappas, S., Cheeta, S., Muscat, R. Psychopharmacology (Berl.) (1994) [Pubmed]
  16. Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole. Takata, K., Kitamura, Y., Kakimura, J., Kohno, Y., Taniguchi, T. Brain Res. (2000) [Pubmed]
  17. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease : A national multicenter parallel-group randomized study. Barone, P., Scarzella, L., Marconi, R., Antonini, A., Morgante, L., Bracco, F., Zappia, M., Musch, B. J. Neurol. (2006) [Pubmed]
  18. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Maj, J., Rogóz, Z., Skuza, G., Kołodziejczyk, K. Eur. J. Pharmacol. (1997) [Pubmed]
  19. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Kompoliti, K., Adler, C.H., Raman, R., Pincus, J.H., Leibowitz, M.T., Ferry, J.J., Blasucci, L., Caviness, J.N., Leurgans, S., Chase, W.M., Yones, L.C., Tan, E., Carvey, P., Goetz, C.G. Neurology (2002) [Pubmed]
  20. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. Gu, M., Iravani, M.M., Irvani, M., Cooper, J.M., King, D., Jenner, P., Schapira, A.H. J. Neurochem. (2004) [Pubmed]
  21. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. Maggio, R., Scarselli, M., Novi, F., Millan, M.J., Corsini, G.U. J. Neurochem. (2003) [Pubmed]
  22. Pramipexole protects against MPTP toxicity in non-human primates. Iravani, M.M., Haddon, C.O., Cooper, J.M., Jenner, P., Schapira, A.H. J. Neurochem. (2006) [Pubmed]
  23. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Presgraves, S.P., Borwege, S., Millan, M.J., Joyce, J.N. Exp. Neurol. (2004) [Pubmed]
  24. Pramipexole protects against H(2)O(2)-induced PC12 cell death. Fujita, Y., Izawa, Y., Ali, N., Kanematsu, Y., Tsuchiya, K., Hamano, S., Tamaki, T., Yoshizumi, M. Naunyn Schmiedebergs Arch. Pharmacol. (2006) [Pubmed]
  25. Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. Lorenc-Koci, E., Wolfarth, S. Eur. J. Pharmacol. (1999) [Pubmed]
  26. Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropinirole. Olanow, C.W., Schapira, A.H., Roth, T. Neurology (2000) [Pubmed]
  27. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Schilling, J.C., Adamus, W.S., Palluk, R. Clin. Pharmacol. Ther. (1992) [Pubmed]
  28. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. Abramova, N.A., Cassarino, D.S., Khan, S.M., Painter, T.W., Bennett, J.P. J. Neurosci. Res. (2002) [Pubmed]
  29. Dopamine agonists in schizophrenia: a review. Benkert, O., Müller-Siecheneder, F., Wetzel, H. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. (1995) [Pubmed]
  30. Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Kakimura, J., Kitamura, Y., Takata, K., Kohno, Y., Nomura, Y., Taniguchi, T. Eur. J. Pharmacol. (2001) [Pubmed]
  31. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Guttman, M., Stewart, D., Hussey, D., Wilson, A., Houle, S., Kish, S. Neurology (2001) [Pubmed]
  32. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Guttman, M. Neurology (1997) [Pubmed]
  33. Pramipexole-induced somnolence and episodes of daytime sleep. Hauser, R.A., Gauger, L., Anderson, W.M., Zesiewicz, T.A. Mov. Disord. (2000) [Pubmed]
  34. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. Wright, C.E., Sisson, T.L., Ichhpurani, A.K., Peters, G.R. Journal of clinical pharmacology. (1997) [Pubmed]
WikiGenes - Universities